As we head toward the end of the year, the Oncology Journal Club Podcast team reflect on learnings from the last big international conference of the year – ESMO 2024.
With 15 papers across various specialties, we’ve got you covered with an insightful exploration of all the pivotal studies. You can expect expert analysis alongside our unique blend of humour, banter and bad dad jokes.
With our incredible Hosts – Professor Craig Underhill, Dr Kate Clarke and Professor Christopher Jackson.
About The Oncology Journal Club:
We have taken an old concept and updated it with a new format. In each episode, a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.
We hope you enjoy listening and find this a valuable and entertaining resource.
PAPERS:
MAIN PAPERS
CJ:
Rao, S. et al. LBA2 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo). Annals of Oncology, Volume 35, S1217. Access online here.
Leong,T. et al. Preoperative Chemoradiotherapy for Resectable Gastric Cancer. N Engl J Med. Published September 13, 2024. Access online here.
Janjigia, Y.Y. et al. Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma. Annals of Oncology (2024) 35 (suppl_2): S878-S912. 10.1016/annonc/annonc1603. Access online here.
Kang, Y. et al. First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW. Annals of Oncology (2024) 35 (suppl_2): S878-S912. 10.1016/annonc/annonc1603. Access online here.
Groarke JD, et al. Ponsegromab for the Treatment of Cancer Cachexia. NEJM; Published online 14 September 2024. Access online here.
Kate:
Lurain K, et al. Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma. J Clin Oncol. 2024 Oct 2:JCO2400640. doi: 10.1200/JCO.24.00640. Epub ahead of print. PMID: 39356983. Access online here.
Chan JA, et al. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2024 Sep 16. doi: 10.1056/NEJMoa2403991. Epub ahead of print. PMID: 39282913. Access online here.
Schmid P, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2409932. Epub ahead of print. PMID: 39282906. Access online here.
Craig:
Jayan A, et al Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab. JCO Oncol Pract. 2024 Oct 10:OP2400371. doi: 10.1200/OP.24.00371. Epub ahead of print. PMID: 39388649. Access online here.
Powles, T.B. et al. A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA). Annals of Oncology (2024) 35 (suppl_2): 1-72. 10.1016/annonc/annonc1623. Access online here.
Cheng, Y. et al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. Published September 13, 2024. N Engl J Med 2024;391:1313-1327. Access online here.
Seguchi, K. et al. Impact of MTAP loss on prognosis and efficacy of immune check point inhibitors across advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-1. Annals of Oncology (2024) 35 (suppl_2): S238-S308. 10.1016/annonc/annonc1576. Access online here.
Park, W. et al. Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC). Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc158. Access online here.
Blow Your Own Trumpet Paper:
FDA Guidance: Conducting Clinical Trials With Decentralized Elements. September 2024. Docket Number: FDA-2022-D-2870. Access online here.
Other Papers Mentioned:
Larkin, J, et al. 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma. Annals of Oncology (2024) 35 (suppl_2): 1-72. 10.1016/annonc/annonc1623. Access online here.
HOSTS:
Craig Underhill
Professor Craig Underhill
Professor Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.
In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.
Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.
You can find Craig on X/Twitter here: @CraigUnderhill
Kate Clarke
Dr. Kate Clarke
Dr Kate Clarke (MBChB (Otago), FRACP) is a proud New Zealander with a real love for beautiful Aotearoa. Dr Clarke continues to work at being Tangata Tiriti. Much of her research and patient advocacy has an equity focus. Dr Clarke is grateful to her patients, students, whanau and colleagues for the knowledge and awhi they share. Ehara taku toa, he takitahi, he toa takitini.
Dr Clarke completed her medical training in Otago, Wellington and London. She has a holistic approach and is passionate about patient-centred care, and believes patients can and should play an active role in their healthcare. Her clinical experience covers a broad range of solid tumour malignancies with special clinical interest in colorectal cancer, upper gastrointestinal cancers and breast cancer.
Chris ‘CJ’ Jackson
Professor Christopher Jackson
Chris Jackson is Professor of Medical Oncology at the University of Otago, Dunedin, and a medical oncologist at Dunedin Hospital and Mercy Cancer Care. He specialises in GI cancers and melanoma, teaches medical students and specialists-in-training, and is heavily involved in both national and international cancer policy, leadership and research.
He was previously the medical director of the Cancer Society of NZ, and his advocacy led to the funding of new cancer drugs, to the development of a new national cancer plan, and to the birth of the national cancer agency Te Aho o Te Kahu. He currently chairs the agency’s clinical committee and serves on the advisory board. In addition, he is on the programme board of the International Cancer Benchmarking Project, and is a founding member of the Common Sense Oncology movement.
Chris is a self-confessed Radiohead tragic, and recent convert to Crossfit (even though you didn’t ask).
Connect with CJ on X/Twitter: @drkiwicj
PRODUCER:
Rachael Babin
Rachael Babin is Host of The Oncology Podcast, Editor-in-Chief of The Oncology Newsletter, and Publisher of Oncology News Australia and The Oncology Network.
With a background in oncology communications and academic publishing, Rachael is happiest sitting behind the mic chatting to interesting people about the impact their work makes in oncology.
Connect on Twitter: @OncologyNewsAus
